AEs Related to Olaparib Treatment May Be Easily Mitigated in High-Risk Early Breast Cancer
December 10th 2021Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with germline BRCA1/2 mutations in patients with high-risk, HER2-negative, early-stage breast cancer.
Samuraciclib Plus Fulvestrant Improves PFS in Heavily Pretreated HR+ Breast Cancer
Fulvestrant plus the CDK7 inhibitor samuraciclib demonstrated encouraging efficacy in patients with hormone receptor-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.
Subgroup Analyses Support T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer
December 9th 2021Trastuzumab deruxtecan led to prolonged progression-free survival and higher responses vs trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer across all patients subgroups, including those with and without baseline brain metastases.
Adjuvant Approaches Reduce Risk of Distant Recurrence in HER2+ Early Stage Breast Cancer
December 9th 2021Adjuvant treatment with neratinib or ado-trastuzumab emtansine resulted in a greater reduction in the risk of disease recurrence compared with other therapies in an epidemiologic model of HER2-positive, early-stage breast cancer.
Zanidatamab/Chemo Showcases Early Safety, Antitumor Activity in HER2+ Breast Cancer
The addition of the bispecific antibody zanidatamab to single-agent chemotherapy was found to produce promising antitumor activity with acceptable tolerability in heavily pretreated patients with HER2-positive breast cancer.
Tucatinib Plus Palbociclib/Letrozole Prolongs CNS-PFS in HR+/HER2+ Breast Cancer
A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole resulted in prolonged central nervous system progression-free survival in patients with hormone receptor–positive, HER2-positive breast cancer.
Aromatase Inhibitors Significantly Reduce Recurrence in Premenopausal ER+ Breast Cancer
December 8th 2021Aromatase inhibitors significantly reduced the risk of breast cancer recurrence in premenopausal women with estrogen receptor–positive breast cancer receiving ovarian suppression compared with tamoxifen.
New Data Support Use of Palbociclib in Black and Hispanic Patients With HR+, HER2– Breast Cancer
December 8th 2021Safety and efficacy data from a pooled pooled analysis confirm that patients who are Black or Hispanic with hormone receptor–positive, HER2-negative breast cancer can be treated with palbociclib plus endocrine therapy.
Standard IHC Assays Show Poor Accuracy in Identifying Low HER2 Expression in Breast Cancer
December 8th 2021Survey data collected from more than 1400 laboratories around the world have demonstrated poor agreement in the evaluation of patients with breast cancer who have a low HER2 immunohistochemistry score of 0 or 1+ using standard HER2 assays.
Higher Oncotype DX Scores Predict for Improved Endocrine Therapy Compliance in ER+ Breast Cancer
December 8th 2021Higher Oncotype DX recurrence scores were associated with prolonged persistence to 5 years of endocrine therapy vs lower Oncotype DX recurrence scores in patients with low-risk, estrogen receptor-positive/progesterone receptor–positive breast cancer, according to findings from a retrospective review.
Entinostat/Exemestane Improves PFS in Chinese Patients With Advanced HR+ Breast Cancer
The combination of entinostat and exemestane led to a significant improvement in progression-free survival compared with placebo and exemestane in Chinese patients with advanced hormone receptor–positive breast cancer.
Adjuvant Pembrolizumab Sustains Benefit Across TNBC Subgroups
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab resulted in a statistically significant and clinically meaningful improvement in event-free survival in patients with early-stage triple negative breast cancer.